Notice of Closed Meeting, 11547 [2019-05832]
Download as PDF
<![CDATA[
Federal Register / Vol. 84, No. 59 / Wednesday, March 27, 2019 / Notices
process. Accordingly, such information
is afforded confidential treatment under
exemption 8 of the Freedom of
Information Act (FOIA), which protects
information from disclosure that is
contained in or related to the
examination or supervision of a
financial institution. 5 U.S.C. 552(b)(8).
In addition, the information may also be
kept confidential under exemption 4 of
the FOIA, which protects trade secrets
or confidential commercial or financial
information. 5 U.S.C. 552(b)(4). In
limited circumstances, aggregate data
for multiple respondents, which does
not reveal the identity of any individual
respondent, may be released.
Current actions: On December 28,
2019, the Board published a notice in
the Federal Register (83 FR 67285)
requesting public comment for 60 days
on the extension, with revision, of the
FR 2052a. On September 12, 2018, the
Board temporarily approved 3 certain
revisions to the FR 2052a relating to the
Economic Growth, Regulatory Relief,
and Consumer Protection Act and the
Board’s related interim final rule
amending the treatment of certain
municipal obligations that are liquid
and readily marketable as high quality
liquid assets (HQLAs) under the LCR
rule.4 Specifically, the Board amended
the Assets Category Table in Appendix
III of the FR 2052a such that the
description of the asset classification
code ‘‘IG2–Q’’ is sufficiently inclusive
of municipal obligations that may
qualify as HQLAs under the LCR rule.
The comment period for this notice
expired on February 26, 2019. The
Board did not receive any comments.
The revisions will be implemented as
proposed. Board of Governors of the
Federal Reserve System, March 22,
2019.
Michele Taylor Fennell,
Assistant Secretary of the Board.
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended, and the Determination of
the Chief Operating Officer, CDC,
pursuant to Public Law 92–463. The
grant applications and the discussions
could disclose confidential trade secrets
or commercial property such as
patentable material, and personal
information concerning individuals
associated with the grant applications,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Disease,
Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)—
RFA–IP19–004, Network of Forecasting
Centers to Improve Forecast Accuracy
and Communication for Seasonal and
Pandemic Influenza.
Date: May 22, 2019.
Time: 10:00 a.m.–5:00 p.m., (EDT).
Place: Teleconference, Centers for
Disease Control and Prevention, Room
1080, 8 Corporate Square Blvd., Atlanta,
GA 30329.
Agenda: To review and evaluate grant
applications.
FOR FURTHER INFORMATION CONTACT:
Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600
Clifton Road NE, Mailstop E60, Atlanta,
Georgia 30329, (404) 718–8833, gca5@
cdc.gov.
The Chief Operating Officer, Centers
for Disease Control and Prevention, has
been delegated the authority to sign
Federal Register notices pertaining to
announcements of meetings and other
committee management activities, for
both the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2019–05832 Filed 3–26–19; 8:45 am]
[FR Doc. 2019–05841 Filed 3–26–19; 8:45 am]
BILLING CODE 4163–18–P
BILLING CODE P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Cancellation of Meeting: The
Secretary’s Advisory Committee on
Human Research Protections
Centers for Disease Control and
Prevention
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
3 See
4 See
83 FR 46163 (September 12, 2018).
83 FR 44451 (August 31, 2018).
VerDate Sep<11>2014
21:13 Mar 26, 2019
Office of the Assistant
Secretary for Health, Office of the
Secretary, Department of Health and
Human Services.
ACTION: Notice.
AGENCY:
Notice of Closed Meeting
Jkt 247001
Pursuant to Section 10(a) of
the Federal Advisory Committee Act,
notice is hereby given that the meeting
of the Secretary’s Advisory Committee
on Human Research Protections
SUMMARY:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
11547
(SACHRP), scheduled to occur March 27
and 28, 2019, at 6700B Rockledge Drive,
Suite 1102, Bethesda MD 20892, has
been cancelled. The Federal Register
Notice announcing this meeting
appeared March 11, 2019. The next
meeting is scheduled for July 30 and 31,
2019.
FOR FURTHER INFORMATION CONTACT: Julia
Gorey, J.D., Executive Director,
SACHRP; U.S. Department of Health
and Human Services, 1101 Wootton
Parkway, Suite 200, Rockville,
Maryland 20852; telephone: 240–453–
8141; fax: 240–453–6909; email address:
SACHRP@hhs.gov.
SUPPLEMENTARY INFORMATION: Under the
authority of 42 U.S.C. 217a, Section 222
of the Public Health Service Act, as
amended, SACHRP was established to
provide expert advice and
recommendations to the Secretary of
Health and Human Services, through
the Assistant Secretary for Health, on
issues and topics pertaining to or
associated with the protection of human
research subjects.
Dated: March 19, 2019.
Julia G. Gorey,
Executive Director, Secretary’s Advisory
Committee on Human Research Protections.
[FR Doc. 2019–05801 Filed 3–26–19; 8:45 am]
BILLING CODE 4150–36–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; PAR–17–123:
Biomarkers for Diabetes, Digestive, Kidney
and Urologic Diseases using NIDDK
Biorepository Samples (R01).
Date: May 6, 2019.
Time: 12:00 p.m. to 3:00 p.m.
E:\FR\FM\27MRN1.SGM
27MRN1
]]>Agencies
[Federal Register Volume 84, Number 59 (Wednesday, March 27, 2019)]
[Notices]
[Page 11547]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-05832]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended, and the Determination of the Chief Operating
Officer, CDC, pursuant to Public Law 92-463. The grant applications and
the discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: Disease, Disability, and Injury Prevention and
Control Special Emphasis Panel (SEP)--RFA-IP19-004, Network of
Forecasting Centers to Improve Forecast Accuracy and Communication for
Seasonal and Pandemic Influenza.
Date: May 22, 2019.
Time: 10:00 a.m.-5:00 p.m., (EDT).
Place: Teleconference, Centers for Disease Control and Prevention,
Room 1080, 8 Corporate Square Blvd., Atlanta, GA 30329.
Agenda: To review and evaluate grant applications.
FOR FURTHER INFORMATION CONTACT: Gregory Anderson, M.S., M.P.H.,
Scientific Review Officer, CDC, 1600 Clifton Road NE, Mailstop E60,
Atlanta, Georgia 30329, (404) 718-8833, gca5@cdc.gov.
The Chief Operating Officer, Centers for Disease Control and
Prevention, has been delegated the authority to sign Federal Register
notices pertaining to announcements of meetings and other committee
management activities, for both the Centers for Disease Control and
Prevention and the Agency for Toxic Substances and Disease Registry.
Sherri Berger,
Chief Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2019-05832 Filed 3-26-19; 8:45 am]
BILLING CODE 4163-18-P
